Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIFF-flu
- Development stage
- Unknown
- Lead developer
- Vivaldi Biosciences
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
DIFF-flu is a live-attenuated influenza vaccine (LAIV) candidate developed by Vivaldi Biosciences using its proprietary Delta-NS1 (DELNS1) technology. The vaccine consists of influenza virus strains in which the gene for Non-Structural protein 1 (NS1) has been deleted. NS1 is the primary viral protein responsible for antagonizing the host's innate immune response, specifically by blocking the production of interferon. By removing this gene, the vaccine virus becomes replication-deficient in normal human cells but remains highly immunogenic. Upon intranasal administration, DIFF-flu induces a rapid and robust localized interferon response, which acts as a natural adjuvant to stimulate broad-spectrum immunity, including mucosal IgA, systemic IgG, and T-cell responses. This mechanism is designed to provide superior protection against both homologous and heterologous (drifted) influenza strains compared to traditional inactivated or live-attenuated vaccines.
- Other names
- Delta-NS1 influenza vaccineDelta-NS-1 influenza vaccineDelta-NS 1 influenza vaccineNS1-deleted influenza vaccineNS-1-deleted influenza vaccineNS 1-deleted influenza vaccineDelta-flu
02
Targets
IFN-α (Interferon alpha-7)HA (Hemagglutinin)NeuraminidaseIFN-β (Interferon beta)
Beyond the preview
Go deeper on DIFF-flu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIFF-flu.